Addario Lung Cancer Medical Institute - ALCMI

02/03/2026

Oncogenic p53 in lung cancer does more than disrupt genome integrity. A new study shows that mutant, gain-of-function p53 actively drives a replication-based loop that both accelerates tumor growth and creates a targetable vulnerability.

Mutations in tumor suppressor p53 that gain oncogenic functions (Onc-p53) are frequent in lungs and many other solid tumors often associated with chromosome aberrations. Why cells or tumors with Onc-p53 develop chromosomal aberrations and whether the abnormalities contribute to tumor growth remain e...

02/02/2026

The American College of Radiology, the American Society for Radiation Oncology (ASTRO), and The Society of Thoracic Surgeons have issued a rare joint statement to correct "misinformation" and methodological flaws that distort the perceived risks of lung cancer screening.

Three prominent medical societies are pushing back against what they describe as misleading claims about the risks of lung cancer screening, which they say could hinder screening uptake and lead to advanced and harder-to-treat disease.

02/01/2026

New partnership alert! Bristol Myers Squibb and Microsoft have formed a new strategic partnership to use FDA-cleared radiology AI to detect lung cancer earlier and at scale.

Bristol Myers Squibb and Microsoft Partner to Advance AI-Driven Early Lung Cancer Detection / AI in healthcare, AI in Radiology, Artificial Intelligence in

01/31/2026

Tom Cunningham, PhD, at the University of Cincinnati Cancer Center, is targeting the PRPS enzyme complex as a therapeutic dependency in KRAS-mutated lung cancer, backed by a two-year, $150,000 Lung Cancer Research Foundation grant.

The University of Cincinnati Cancer Center’s Tom Cunningham has received a two-year, $150,000 grant from the Lung Cancer Research Foundation (LCRF) to test approaches to neutralize an enzyme complex that plays a vital role in the growth of KRAS-mutated lung cancers.

01/30/2026

A history of tuberculosis and chronic bronchitis increases lung cancer risk in people who have never smoked, according to a new systematic review.

History of TB and CB were associated with increased lung cancer risk among populations with no smoking history. Future studies examining these associations should analyze more diverse populations and disaggregate findings by s*x, race/ethnicity, and socioeconomic status.

01/17/2026

Christian Jobin, Ph.D., and Rachel Newsome, Ph.D., at UF Health Cancer Institute have identified a gut microbiota–derived metabolite, Bac429, that materially increases immunotherapy activity in lung cancer models and is now being advanced into a drug candidate.

GAINESVILLE, Fla. — UF Health Cancer Institute researchers have discovered a small compound produced naturally by gut bacteria that doubled the response to…

01/16/2026

Catherine Sears, MD, and colleagues at Indiana University are linking impaired DNA repair to the shared biology of emphysema and lung cancer.

Dr. Catherine Sears’ research seeks to change the way COPD and lung cancer are treated.

01/15/2026

Zoldonrasib just became the first investigational KRAS G12D targeted therapy in NSCLC to receive FDA Breakthrough Therapy Designation, based on Phase 1 monotherapy data from Revolution Medicines.

01/14/2026

Basal stem cells, not neuroendocrine cells, may be the initiating cell of origin for small-cell lung cancer, according to Trudy Oliver.

The study, published in British scientific journal Nature, suggests that the disease may begin in basal stem cells — long-lived cells that help repair and replace damaged tissue in the lungs — contradicting what scientists have thought for decades.

01/13/2026

Olvi-Vec delivered durable systemic activity in platinum-relapsed lung cancer, with up to 85% tumor shrinkage reported by Genelux in interim trial data published by RTTNews.

01/12/2026

Six FDA approvals in December 2025 expanded the oncology toolbox across blood cancers, prostate cancer, lung cancer, and supportive care, as reported in Cure.

The FDA approved six new therapies for blood, prostate and lung cancers and supportive care, expanding treatment options based on recent trials.

01/11/2026

Check this out! AstraZeneca is re-running Datroway in relapsed NSCLC with a biomarker-enriched phase 3 design that directly addresses the Tropion-Lung01 miss.

Data insights Datroway’s Tropion-Lung01 do-over? 2 January 2026   Jacob Plieth   AstraZeneca, still awaiting the key catalyst of Datroway’s Avanzar study readout, recently took this TROP2-targeting ADC into a phase 3 trial in the tough setting of relapsed non-small cell lung cancer. The trial ...